Cargando…

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes

BACKGROUND: Tiotropium Safety and Performance in Respimat® (TIOSPIR®) compared the safety and efficacy of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anzueto, Antonio, Wise, Robert, Calverley, Peter, Dusser, Daniel, Tang, Wenbo, Metzdorf, Norbert, Dahl, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570597/ https://www.ncbi.nlm.nih.gov/pubmed/26369563 http://dx.doi.org/10.1186/s12931-015-0269-4

Ejemplares similares

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
por: Wise, Robert A, et al.
Publicado: (2013)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
por: Calverley, Peter MA, et al.
Publicado: (2017)

Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial
por: Dusser, Daniel, et al.
Publicado: (2016)

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(®) trial
por: Wise, Robert A, et al.
Publicado: (2018)

Tiotropium safety in ‘real‐world’ populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology
por: Wise, Robert, et al.
Publicado: (2016)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Discordance in investigator-reported and adjudicated sudden death in TIOSPIR
por: Wise, Robert A., et al.
Publicado: (2017)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
por: Calverley, Peter MA, et al.
Publicado: (2018)

Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2016)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

Efficacy and safety of tiotropium Respimat(®) SMI in COPD in two 1-year randomized studies
por: Bateman, Eric, et al.
Publicado: (2010)

Safety of tiotropium in patients with asthma
por: Dusser, Daniel, et al.
Publicado: (2019)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial
por: Tashkin, Donald P, et al.
Publicado: (2015)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Tiotropium might improve survival in subjects with COPD at high risk of mortality
por: Burgel, Pierre-Régis, et al.
Publicado: (2014)

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results
por: Bradley, Judy M., et al.
Publicado: (2014)

Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD
por: Calverley, Peter M. A., et al.
Publicado: (2016)

Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies
por: LaForce, Craig, et al.
Publicado: (2018)

Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study
por: Trotta, Francesco, et al.
Publicado: (2017)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study
por: Trotta, Francesco, et al.
Publicado: (2015)

Tiotropium respimat(®) add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status
por: Yang, WH, et al.
Publicado: (2014)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma
por: Beeh, Kai-Michael, et al.
Publicado: (2014)

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Bronchodilator Effect of Tiotropium via Respimat(Ⓡ) Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD)
por: Ogasawara, Takashi, et al.
Publicado: (2017)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies
por: ZuWallack, Richard, et al.
Publicado: (2014)

Burden of Asthma and Role of 2.5 µg Tiotropium Respimat(®) as an Add-On Therapy: A Systematic Review of Phase 2/3 Trials
por: Mansfield, Lyndon, et al.
Publicado: (2019)

Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy
por: Carone, Mauro, et al.
Publicado: (2020)

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease
por: Miravitlles, Marc, et al.
Publicado: (2015)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
por: Anzueto, Antonio, et al.
Publicado: (2020)

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat(®) Soft Mist(™) Inhaler: findings from two dose-ranging studies in healthy men
por: Feifel, Ulrich, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ps2knedi1ro2rcp30v1un1jpr6